Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

888.07 -8.93 (-1.00%)
Streaming Delayed Price Updated: 1:59 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development. 
Via The Motley Fool
News headline image
Should You Avoid Pfizer? Here's the Key Risk to Watch ↗
Pfizer has reached a turning point. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? ↗
Eli Lilly's stock is down this year, and its high valuation may be a big reason why. 
Via The Motley Fool
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending. 
Via The Motley Fool
News headline image
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial ↗
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients. 
Via Benzinga
News headline image
3 Companies at the Forefront of the GLP-1 Pill Wars ↗
Via MarketBeat
News headline image
3 Quality Compounders to Own for Decades
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr... 
Via StockStory
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials. 
Via The Motley Fool
News headline image
3 Stocks That Could Be Next to Announce a Stock Split ↗
Via MarketBeat
News headline image
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand ↗
Via MarketBeat
News headline image
Is Eli Lilly's Weight Loss Empire in Trouble? ↗
It won't be easy to knock the company off its pedestal. 
Via The Motley Fool
News headline image
The Great Rotation: Investors Retreat to Defensive Fortresses as 2026 Market Volatility Bites
As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and... 
Via MarketMinute
Topics Economy Stocks
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Real Reason Eli Lilly Is Pouring $3 Billion Into China ↗
Via MarketBeat
News headline image
Kroger Shares Rise As Pharmacies Add Eli Lilly's Zepbound KwikPen ↗
Kroger shares edged higher Friday after the Cincinnati-based grocer expanded access to Lilly's Zepbound KwikPen. 
Via Benzinga
News headline image
The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from... 
Via Finterra
Topics Economy
News headline image
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 ↗
Eli Lilly warns that an impurity formed in compounded tirzepatide mixed with vitamin B12 could pose unknown health risks. 
Via Benzinga
News headline image
Should You Chase the Rally in Hims & Hers Stock Today?
Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here. 
Via Barchart.com
News headline image
Does This Deal Make Novo Nordisk Stock a Buy? ↗
Not many things have gone right for Novo Nordisk recently, but this is one of them. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
Via Finterra
Topics Economy
News headline image
The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers... 
Via Finterra
News headline image
Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years ↗
Via MarketBeat
News headline image
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline ↗
AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June. 
Via Benzinga
News headline image
Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner ↗
A new battle between these longtime rival companies will likely go the same way as their previous battles. 
Via The Motley Fool
News headline image
Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
The Dow’s Anchor: How UnitedHealth’s ‘Great Reset’ is Dragging Down the Blue-Chip Average
As of March 11, 2026, the Dow Jones Industrial Average is grappling with a heavyweight problem. UnitedHealth Group (NYSE: UNH), long the gold standard of the managed care sector and a primary engine of... 
Via MarketMinute
Topics Stocks
News headline image
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound ↗
Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't... 
Via Benzinga
News headline image
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗
Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.